Event Panel Schedule

Stefan Loren, Ph.D., Managing Director / Oppenheimer & Co. Inc. Info

Loren is a managing director at Oppenheimer & Co.. Prior to joining Oppenheimer Loren was managing partner at Leap Day Capital (2014-2017) and board director for GenVec (2013-2017). Loren graduated with a PhD. in Organic/Pharmaceutical… [show more]

Loren is a managing director at Oppenheimer & Co.. Prior to joining Oppenheimer Loren was managing partner at Leap Day Capital (2014-2017) and board director for GenVec (2013-2017). Loren graduated with a PhD. in Organic/Pharmaceutical Chemistry at University of California. [hide]

Michael A. Margolis, R.Ph., Co-Head of Healthcare Investment Banking / Oppenheimer & Co. Inc. Info

Mr. Michael Margolis serves as Co-Head of Healthcare Investment Banking at Oppenheimer & Company. He served as a Managing Director, Healthcare Investment Banking at Roth Capital Partners. He was most recently a Managing Director of Healthcare… [show more]

Mr. Michael Margolis serves as Co-Head of Healthcare Investment Banking at Oppenheimer & Company. He served as a Managing Director, Healthcare Investment Banking at Roth Capital Partners. He was most recently a Managing Director of Healthcare investment banking at Merriman Curhan Ford. Previously Mr. Margolis was a senior vice president at Rodman & Renshaw. He had extensive financial and pharmaceutical industry experience before joining Rodman. Mr. Margolis worked at Novartis Pharmaceuticals Corporation in several roles, including as a director in the global business development and licensing group. He was an equity research analyst at Ursus Capital, and he began his career at Eli Lilly & Company as a senior pharmaceutical representative. Mr. Margolis throughout his career has executed a significant number of banking and strategic transactions across all healthcare sectors. He is a registered pharmacist with an M.B.A. from New York University's Stern School of Business and a pharmacy degree from Rutgers University, College of Pharmacy. [hide]

Rajiv Shukla, Chairman & CEO / Alpha Healthcare Acquisition Info

Alpha Healthcare Acquisition Corp is led by Chairman and CEO, Rajiv Shukla. Rajiv is a long-time healthcare investor and 3-time public company CEO. His previous SPAC acquired DermTech, a disruptive non-invasive cancer diagnostic company. DMTK stock… [show more]

Alpha Healthcare Acquisition Corp is led by Chairman and CEO, Rajiv Shukla. Rajiv is a long-time healthcare investor and 3-time public company CEO. His previous SPAC acquired DermTech, a disruptive non-invasive cancer diagnostic company. DMTK stock reached 7x the transaction price (as of closing Jan 25, 2021) and is among the best performing healthcare SPACs of all time. Previously, Rajiv served as CEO of a 4,000-person, ~$3.5 billion EV company that he restructured and sold. Earlier, he served as Portfolio Manager of a healthcare hedge fund at Morgan Stanley and as a private equity investor at CVCI. Before moving to principal investing, Rajiv served as Global M&A lead for Pfizer Global R&D in New London, CT. Rajiv graduated with a Masters in Healthcare Management from Harvard University and a Bachelors in Pharmaceutics from the Indian Institute of Technology. [hide]

Michael Celano, CFO / Larimar Therapeutics Info

Michael Celano joined Larimar Therapeutics in June 2020, as Chief Financial Officer (CFO). He brings over 30 years’ experience as a life science business leader with a broad skill set including capital raising, creative financing structures, investor… [show more]

Michael Celano joined Larimar Therapeutics in June 2020, as Chief Financial Officer (CFO). He brings over 30 years’ experience as a life science business leader with a broad skill set including capital raising, creative financing structures, investor relations, business development, manufacturing, tax planning, SEC compliance, and general business activities. Since transitioning from his public accounting career, Mr. Celano spent more than 15 years as a Chief Operating Officer (COO), CFO and board member with a series of high-growth life science companies. He is currently the Chairman of the Board of Directors (previously the audit committee chair) of OraSure Technologies, a molecular tools and diagnostic company. Mr. Celano was also on the Board of Performance Health, a private equity funded consumer healthcare products company sold to Patterson Medical in a dual track IPO / business sale process. Most recently, he was the COO and previously the CFO of Recro Pharma, a specialty pharmaceutical company. Mr. Celano also served as CFO of Kensey Nash until its acquisition by DSM. Previously, he served as CFO for BioRexis, which was sold to Pfizer. Before joining BioRexis, Mr. Celano spent 24 years in public accounting, where he co-chaired Andersen’s U.S. Life Sciences Practice. After leaving Andersen, he held similar leadership positions with KPMG. Mr. Celano received his BS in accounting from St Joseph’s University. [hide]

Jennifer Porcelli, Managing Director / Solebury Trout Info

Jen Porcelli is a Managing Director in the New York office. Jen works with a broad spectrum of privately-held and publicly-traded life sciences companies throughout various stages of the funding lifecycle; she provides management teams with… [show more]

Jen Porcelli is a Managing Director in the New York office. Jen works with a broad spectrum of privately-held and publicly-traded life sciences companies throughout various stages of the funding lifecycle; she provides management teams with strategic advice surrounding a variety of investor relations initiatives and conducts targeted outreach to the institutional investor community to identify potential investors and long-term shareholders. She joined the firm in 2015. Recent and ongoing assignments include: * Advised CNS-focused company around Phase 3 data announcement and subsequent key opinion leader (KOL) event at a medical meeting * Planned and coordinated several KOL events and non-deal roadshows for TiGenix NV prior to their acquisition by Takeda Pharmaceutical Co * Advised EU-listed Immuno-Oncology company on banker, sell-side analyst, and investor targeting to propel successful private placement to US institutional investors Prior to joining Solebury Trout, Jen worked on the UBS Investment Bank Corporate Access desk within the Institutional Sales & Trading team, where she spent more than 11 years helping companies across a broad range of sectors with their investor targeting efforts. Prior to that, she worked on the UBS Healthcare Investment Banking team, primarily focused on developing internal & external communications. Jen began her career at JPMorgan on the Investment Bank Marketing team. Jen holds a B.S. in Marketing & Communications from Georgetown University. During her time at Georgetown, Jen worked on Capitol Hill for Senator Tim Johnson (SD) and completed three Marine Corps Marathons. Jen holds Series 7, 79, and 63 securities licenses. She enjoys running, rowing, and spending time with her husband and three kids. [hide]

Joel Rubinstein, Partner / White & Case LLP Info

Joel Rubinstein is a partner at White & Case, and a member of the Firm’s Capital Markets Practice. Joel has broad experience in corporate and securities matters, representing clients in public offerings and private placements of securities… [show more]

Joel Rubinstein is a partner at White & Case, and a member of the Firm’s Capital Markets Practice. Joel has broad experience in corporate and securities matters, representing clients in public offerings and private placements of securities, complex business transactions, including private and public company mergers and acquisitions, and in organizing and investing in private investment funds. Joel has particular expertise in advising issuers, underwriters and investment funds on the IPOs of special-purpose acquisition companies (SPACs), as well as M&A transactions between SPACs and operating companies. He has represented clients in more than 30 SPAC IPOs, raising aggregate gross proceeds of more than US$8 billion, and in more than 15 business combination transactions with an aggregate enterprise value of more than US$11 billion. [hide]

Stuart Bressman, Partner / White & Case LLP Info

Stuart advises investment banks and issuers on public and private securities offerings by US and non-US companies. Clients also seek him out for his market-leading experience in alternative financing techniques, such as confidentially marketed public… [show more]

Stuart advises investment banks and issuers on public and private securities offerings by US and non-US companies. Clients also seek him out for his market-leading experience in alternative financing techniques, such as confidentially marketed public offerings, bought deals, registered direct offerings and private investments in public equity. Over his career, Stuart has completed hundreds of public offerings and private placements of securities as well as other kinds of transactions. Stuart has particular experience across the biotechnology, pharmaceutical, technology and energy industries, and advises clients on corporate and securities compliance and reporting matters. [hide]